ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 436

Poor Concordance Between Remission Judged by Physicians and a Patient-Acceptable Symptom State in Psoriatic Arthritis

Rubén Queiro1, Estefania Pardo 1, Lilyan Charca 1, Sara Alonso 1, L. Arboleya 2 and Mercedes Alperi-López 1, 1Hospital Universitario Central de Asturias, Oviedo, Spain, 2Hospital Central Asturias, OViedo

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Both the evaluation of disease activity in psoriatic arthritis (PsA) and the determination of the impact of the disease on patients’ lives are subjects of intense research at present. Our objective was to evaluate the concordance between the state of clinical remission and an acceptable symptomatic state for patients.

Methods: Post hoc analysis of a multicentre study that included 223 patients with PsA treated with biologic and non-biologic drugs. Remission was defined according to the evaluating physicians and DAPSA definitions. DAPSA score was calculated by adding the number of tender and swollen joints, VAS pain, patient-reported global assessement (PtGA), and CRP (mg/dl). The cDAPSA was calculated without the contribution of CRP. DAPSA and cDAPSA score ≤ 4 identified clinical remissions.

A descriptive statistical analysis of all the variables was performed, including central tendency and dispersion measures for continuous variables, and absolute and relative frequencies for categorical variables. Student’s t-test, Mann-Whitney-U test or Kruskall Wallis H test were used to compare quantitative variables and Pearson’s chi-square or Fisher’s exact tests for qualitative variables. Concordance was assessed using Cohen’s κappa (k) and was considered as follows: < 0.20 = poor, 0.21–0.40 = fair, 0.41–0.60 = moderate, 0.61–0.80 = good, and 0.81–1.00 = very good. Tests were two-tailed with a significance level of 5%. Data were analysed using SPSS V19.0 statistical software.

The PsAID questionnaire reflects the impact of PsA from the patients’ perspective. It is comprised of 12 physical and psychological domains. Each domain is rated from 0 to 10 with a different weighting. Total score is divided by 20. The final score has a range from 0 (best status) to 10 (worst status) with a cutoff of 4. A PsAID value below 4 defines a PASS state.

Results: Of the 223 patients analysed, 122 (54.7%) met the PsAID criterion below 4. The characteristics of this subpopulation are shown in Table 1. There was fair (k: 0.23) and poor (k: 0.17) agreement between joint and cutaneous remission respectively (according to the evaluating physician) and PASS status. the degree of agreement between a complete clinical remission (both cutaneous and articular according to the evaluating physician) and the PASS status was low (k: 0.16, Table 2). There was a moderate agreement (k: 0.46) between DAPSA remission and PASS, while there was almost a good concordance (k: 0.58) between cDAPSA remission and PASS.

Conclusion: The agreement between the state of remission judged by doctors and PASS is quite low. The degree of agreement between DAPSA remission and PASS is better, but it is still moderate. Both DAPSA and PsAID should be included in the routine clinical assessment of patients with PsA, since both offer a superior overall view to that given by each instrument separately.  It is also better to define remission in accordance to a composite index rather than according to physicians´ opinion.


Table 1^


Table 2


Disclosure: R. Queiro, None; E. Pardo, None; L. Charca, None; S. Alonso, None; L. Arboleya, None; M. Alperi-López, None.

To cite this abstract in AMA style:

Queiro R, Pardo E, Charca L, Alonso S, Arboleya L, Alperi-López M. Poor Concordance Between Remission Judged by Physicians and a Patient-Acceptable Symptom State in Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/poor-concordance-between-remission-judged-by-physicians-and-a-patient-acceptable-symptom-state-in-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/poor-concordance-between-remission-judged-by-physicians-and-a-patient-acceptable-symptom-state-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology